New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

Genentech announces optimistic data in aggressive DLBCL

Genentech, a member of the Roche group, announced new data on Thursday related to its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

9

Pfizer’s NASH Treatment Lands FDA Fast Track Designation

On Thursday, Pfizer announced the U.S. Food and Drug Administration granted the company’s combinatorial therapeutic ervogastat/clesacostat Fast Track Designation. The therapeutic combo is intended for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis.